The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.
More Stories
Why now may be a good time to take ‘opportunistic’ profits in gold and silver
Gold prices are at their highest on record and silver recently touched a more than 11-year high. “Upside exhaustion” could...
Stitch Fix’s stock is on pace for its worst drop ever. Here’s what has analysts worried.
Shares of Stitch Fix Inc. plunged toward their biggest percentage drop on record Wednesday, after the online styling service’s quarterly...
Finding a job now is harder than any time since the pandemic. Bad omen for the economy?
Americans say it’s the toughest time to find a job in at least three years. When will it get better?
What 401(k) and IRA moves to make before a nail-biter presidential election like Trump vs. Harris
There is a lot of fear — on both sides.
Expect crypto bulls to flock back to this space now that the Fed is cutting rates
A weekly look at the most important news and moves in crypto, and what’s on the horizon in digital assets.
Buy the stocks of these companies helping fuel the ‘AI gold rush,’ analyst says
With demand for the use of artificial intelligence expected to continue to surge, Oppenheimer analyst Edward Yang recommended investors buy...